Evolent to Participate in Upcoming Investor Conferences [Accessibility Statement] Skip NavigationWASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences.A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor r ...

Core Viewpoint - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors, while also occasionally analyzing large-cap companies to provide a broader perspective on equity markets [1]. Group 1 - The research emphasizes the importance of small- to mid-cap companies in investment analysis due to their potential for growth and the lack of attention they receive from larger investors [1].

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Italy's Leonardo expects aerostructures joint- venture deal by end of June February 25, 20265:25 PM UTCUpdated ago By Reuters ROME, Feb 25 (Reuters) - Italian defence group Leonardo (LDOF.MI), opens new tab expects to sign a joint- venture accord for its aerostructures unit by the end of June, its CEO said on Wednesday, in a protracted deal that could finally allow the loss-making unit to take ...

Core Insights - Evolent Health reported a revenue of $468.72 million for the quarter ended December 2025, reflecting a year-over-year decline of 27.5% [1] - The company's EPS for the same period was $0.08, compared to -$0.02 a year ago, indicating a positive turnaround [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $469.22 million, resulting in a surprise of -0.11%, while the EPS exceeded expectations by 28% [1] Financial Performance - Evolent Health's shares have decreased by 25.3% over the past month, contrasting with the Zacks S&P 500 composite's decline of only 1% [3] - The company currently holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Key Metrics - Average PMPM Fees / Revenue per Case for Performance Suite was $13.87, slightly below the estimated $14.14 [4] - Average Lives on Platform for Cases reached 14 thousand, slightly above the estimated 13.86 thousand [4] - Total Revenue by product type for Performance Suite was $269.46 million, which is a 41% decline compared to the year-ago quarter [4] - Total Revenue by product type for Specialty Technology and Services Suite was $95.74 million, showing a year-over-year increase of 16.3% [4]

分组1 - Evolent Health reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of +28.00% [1] - The company posted revenues of $468.72 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.11%, and this is a decline from year-ago revenues of $646.54 million [2] - Evolent Health shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has only declined by 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $544.44 million, and for the current fiscal year, it is $0.39 on revenues of $2.39 billion [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 40% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Registrant's telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: | Class A Common Stock of Evolent Health, Inc., par value $0.01 per share | EVH | New York Stock Exchange | | --- | --- | --- ...

Evolent Health (NYSE:EVH) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsDavid Larsen - Managing DirectorJailendra Singh - Managing DirectorJared Haase - Senior Research AssociateJeff Garro - Managing DirectorJohn Stansel - Equity Research AssociateKevin Caliendo - Managing DirectorMario Ramos - CFORichard Close - Managing DirectorRyan Halsted - Managing DirectorSeth Blackley - CEONone - Company RepresentativeConference Call ParticipantsDaniel Grosslight - Senior Research AnalystJes ...

Evolent Health (NYSE:EVH) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsDavid Larsen - Managing DirectorJailendra Singh - Managing DirectorJared Haase - Senior Research AssociateJeff Garro - Managing DirectorJohn Stansel - Equity Research AssociateKevin Caliendo - Managing DirectorMario Ramos - CFORichard Close - Managing DirectorRyan Halstead - Managing DirectorSeth Blackley - CEONone - Company RepresentativeConference Call ParticipantsDaniel Grosslight - Senior Research AnalystJe ...

Evolent Health (NYSE:EVH) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Speaker9Welcome to the Evolent Earnings Conference Call for the fourth quarter ended December 31st, 2025. As a reminder, this conference call is being recorded. Your hosts for today's call are Seth Blackley, Chief Executive Officer, and John Johnson, Chief Financial Officer. This call will be archived and available later this evening and for the next week via the webcast on the company's website in the section titled Investor Rela ...

Evolent Health, Inc. Fourth Quarter 2025 Results February 24, 2026 Evolent | Confidential—Do not distribute | 1 Safe Harbor Statement Certain statements made in this report and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, ind ...